Virginia Arrazubi

Virginia Arrazubi

Auto-generated profile, based on publicly available information

Virginia Arrazubi

Department of Oncology, University Hospital of Navarra, Instituto de Investigación Sanitaria de Navarra, IdISNA, Navarra, Spain

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ILIñigo Les
Iñigo Les
MKMIREIA MARTINEZ KAREAGA
MIREIA MARTINEZ KAREAGA
IPInés Pérez-Francisco
Inés Pérez-Francisco
MCMaría Cabero
María Cabero
LTLucía Teijeira
Lucía Teijeira
DEDavid Escors
David Escors
Immune-checkpoint inhibitors (ICIs) are antagonists of inhibitory receptors in the immune system, such as the cytotoxic T-lymphocyte-associated antigen-4, the programmed cell death protein-1 and its ligand PD-L1, and they are increasingly used in cancer treatment. By blocking certain suppressive pathways, ICIs promote T-cell activation and antitumor activity but may induce so-called immune-related adverse events (irAEs), which mimic traditional autoimmune disorders. With the approval of more ICIs, irAE prediction has become a key factor in improving patient survival and quality of life. Several biomarkers have been described as potential irAE predictors, some of them are already available for clinical use and others are under development; examples include circulating blood cell counts and ratios, T-cell expansion and diversification, cytokines, autoantibodies and autoantigens, serum and other biological fluid proteins, human leucocyte antigen genotypes, genetic variations and gene profiles, microRNAs, and the gastrointestinal microbiome. Nevertheless, it is difficult to generalize the application of irAE biomarkers based on the current evidence because most studies have been retrospective, time-limited and restricted to a specific type of cancer, irAE or ICI. Long-term prospective cohorts and real-life studies are needed to assess the predictive capacity of different potential irAE biomarkers, regardless of the ICI type, organ involved or cancer site.

20 November 2017 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
LDL. C. Iglesias Docampo
L. C. Iglesias Docampo
VAV. Arrazubi Arrula
V. Arrazubi Arrula
NBNeus Basté
Neus Basté
AMA. Carral Maseda
A. Carral Maseda
BCB. Cirauqui Cirauqui
B. Cirauqui Cirauqui
JCJuan Jesús Cruz-Hernández
Juan Jesús Cruz-Hernández
Head and neck cancer (HNC) is defined as malignant tumours located in the upper aerodigestive tract and represents 5% of oncologic cases in adults in Spain. More than 90% of these tumours have squamous histology. In an effort to incorporate evidence obtained since 2013 publication, Spanish Society of Medical Oncology (SEOM) presents an update of HNC diagnosis and treatment guideline. The eighth edition of TNM classification, published in January 2017, introduces important changes for p16-positive oropharyngeal tumours, for lip and oral cavity cancer and for N3 category. In addition, there are new data about induction chemotherapy and the role of immunotherapy in HNC.

17 June 2019 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
VAVirginia Arrazubi
Virginia Arrazubi
EMElena Mata
Elena Mata
MAMaría Luisa Antelo
María Luisa Antelo
ATAntonio Tarifa
Antonio Tarifa
JHJavier Herrera
Javier Herrera
RVRuth Vera
Ruth Vera

29 November 2016 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
MMMarta Martin-Richard
Marta Martin-Richard
RBRobert Diaz Beveridge
Robert Diaz Beveridge
VAV. Arrazubi
V. Arrazubi
MAMaría Alsina
María Alsina
MGM. Galan Guzmán
M. Galan Guzmán
FRF. Rivera
F. Rivera
Esophageal cancer (EC) is an aggressive tumor that represents the 6th most common cause of cancer death worldwide. The estimated incidence in Spain is 2090 cases/year. Two main pathological subtypes exist, squamous cell carcinoma and adenocarcinoma. The main differences between them are localization and underlying factors which are the principal cause of the recent incidence changes observed in west countries. Staging techniques and treatment options which combine surgery, chemotherapy and radiotherapy, reflected the high complexity of the EC management. An undeniably multidisciplinary approach is, therefore, required. In this guide, we review the status of current diagnosis and treatment, define evidence and propose recommendations.

18 March 2022 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
ARAntonio Rueda
Antonio Rueda
BCBeatriz Cirauqui
Beatriz Cirauqui
ACAlmudena García Castaño
Almudena García Castaño
RARuth Alvarrz Alvarez
Ruth Alvarrz Alvarez
AMAlberto Carral Maseda
Alberto Carral Maseda
RMRicard Mesia
Ricard Mesia
Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiotherapy (RT) is the cornerstone of locoregional treatment of non-disseminated disease and the association of chemotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy and patients may achieve a long survival time.

21 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ILIbone Labiano
Ibone Labiano
AHAna Elsa Huerta
Ana Elsa Huerta
VAVirginia Arrazubi
Virginia Arrazubi
IHIrene Hernandez-Garcia
Irene Hernandez-Garcia
EMElena Mata
Elena Mata
MAMaría Alsina
María Alsina
Circulating tumor DNA (ctDNA) has emerged as a promising non-invasive source to characterize genetic alterations related to the tumor. Upper gastrointestinal cancers, including gastroesophageal adenocarcinoma (GEC), biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PADC) are poor prognostic malignancies, usually diagnosed at advanced stages when no longer amenable to surgical resection and show a poor prognosis even for resected patients. In this sense, ctDNA has emerged as a promising non-invasive tool with different applications, from early diagnosis to molecular characterization and follow-up of tumor genomic evolution. In this manuscript, novel advances in the field of ctDNA analysis in upper gastrointestinal tumors are presented and discussed. Overall, ctDNA analyses can help in early diagnosis, outperforming current diagnostic approaches. Detection of ctDNA prior to surgery or active treatment is also a prognostic marker that associates with worse survival, while ctDNA detection after surgery is indicative of minimal residual disease, anticipating in some cases the imaging-based detection of progression. In the advanced setting, ctDNA analyses characterize the genetic landscape of the tumor and identify patients for targeted-therapy approaches, and studies show variable concordance levels with tissue-based genetic testing. In this line, several studies also show that ctDNA serves to follow responses to active therapy, especially in targeted approaches, where it can detect multiple resistance mechanisms. Unfortunately, current studies are still limited and observational. Future prospective multi-center and interventional studies, carefully designed to assess the value of ctDNA to help clinical decision-making, will shed light on the real applicability of ctDNA in upper gastrointestinal tumor management. This manuscript presents a review of the evidence available in this field up to date.